Cellectis Revenu Q/Q

Quel est le Revenu Q/Q de Cellectis?

Le Revenu Q/Q de Cellectis est -81.09%

Quelle est la définition de Revenu Q/Q?

La croissance trimestrielle du chiffre d'affaires, d'une année sur l'autre , correspond à l'augmentation du chiffre d'affaires d'une entreprise par rapport à la performance du trimestre correspondant d'un exercice précédent, exprimée en pourcentage.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Revenu Q/Q des entreprises dans Health Care secteur sur NASDAQ par rapport à Cellectis

Que fait Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Entreprises avec revenu q/q similaire à Cellectis